PSI Health Development is located at Level 37, TAIPEI 101 TOWER, No. 7, Sec.5, Xinyi Road, Taipei 110, Taiwan
PSI CRO has announced opening offices in Taiwan, listed as Taiwan PSI Health Development at Level TAIPEI 101 TOWER, Taipei, Taiwan.
“We are excited about the PSI office opening,” said Ava Lu, PSI’s Clinical Operations Manager in Taipei. “We can now bring our staff under the same roof and build a proper PSI home in Taiwan. Our expansion is driven by many clinical trial requests from global sponsors in oncology, infections, IBD (ulcerative colitis, Crohn’s Disease), and other therapeutic areas. We aim to make Taiwan a reliable and consistent contributor to the global clinical trials that PSI manages worldwide. We are keen to keep up with PSI’s unchanging promise of on-time delivery.”
PSI’s expansion into Asia Pacific started in 2017, when PSI opened offices in Sydney, Australia and Seoul, South Korea. PSI is focused on strengthening its global capabilities of delivering clinical trial programs in a variety of therapeutic areas on time and on budget.
“PSI’s global reach in an important differentiator of an agile mid-sized CRO in today’s clinical trial market,” said Katarzyna Skalowska, Global Head of Clinical Operations. “Clinical trials are becoming more complex, while targeting smaller patient populations and requiring a wider geographic spread. PSI is now fully operational on five continents offering robust site relationships with investigators across North America, South America, Africa, Europe, Asia and Australia.”